Caroline Seymour

Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.

Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.

Savolitinib plus osimertinib received breakthrough therapy designation in China for pretreated, locally advanced or metastatic EGFR-positive NSCLC with MET amplification.

T-DXd improved PFS vs treatment of physician’s choice in hormone receptor-positive, HER2-low/-ultralow metastatic breast cancer.

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

A sBLA has been accepted for review seeking the approval of glofitamab plus gemcitabine and oxaliplatin for pretreated, transplant-ineligible patients with relapsed/refractory DLBCL.

The FDA has approved durvalumab for adults with limited-stage small cell lung cancer whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

First-line use of TTFields plus gemcitabine and nab-paclitaxel improved OS vs chemotherapy in unresectable, locally advanced pancreatic adenocarcinoma.

Leo I. Gordon, MD, parses major changes to the 2024 NCCN guidelines for the treatment of patients with MCL, MZL, and follicular lymphoma.

Jonathan Wesley Riess, MD, MS, and Megan E. Daly, MD, provide radiation and medical oncology perspectives on NCCN guideline updates in lung cancer.

Osimertinib has been recommended for approval in patients with locally advanced, unresectable, EGFR-mutant NSCLC after chemoradiation.

The FDA has approved revised drug labeling for fludarabine phosphate under Project Renewal.

The European Commission has approved mirvetuximab soravtansine for select patients with pretreated FRα-positive, platinum-resistant ovarian cancer.

The EMA’s CHMP agency recommended approval for nivolumab plus ipilimumab in patients with MSI-H/dMMR unresectable or metastatic colorectal cancer.

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.

The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Uproleselan plus 7+3 chemotherapy failed to improve EFS vs chemotherapy alone in older patients with newly diagnosed AML fit for intensive chemotherapy.

RMC-9805 was proven safe and active in patients with previously treated, KRAS G12D–mutant pancreatic ductal adenocarcinoma.

The FDA has accepted and granted priority review to the new drug application for the glioma imaging agent TLX101-CDx.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

The Ion Torrent Oncomine Dx Target Test received regulatory approval as a companion diagnostic to identify patients who are eligible for vorasidenib.

The South Korean Ministry of Food and Drug Safety approved selinexor plus bortezomib and dexamethasone for pretreated patients with multiple myeloma.

Perioperative treatment with pembrolizumab and adjuvant radiotherapy improved EFS vs adjuvant radiotherapy in locally advanced head and neck squamous cell carcinoma.

The FDA has approved nivolumab with platinum chemotherapy as neoadjuvant treatment, followed by single-agent nivolumab after surgery, in resectable NSCLC.

The second-generation, BCMA-directed CAR T-cell therapy HBI0101 led to an objective response rate of 92% in patients with relapsed/refractory multiple myeloma.

Maintenance with GRANITE plus fluoropyrimidine, bevacizumab, and checkpoint inhibitors improved PFS vs fluoropyrimidine plus bevacizumab alone in MSS mCRC.